|
No records
|
|
264 |
Lesmana C.R.A., Mandasari B.K.D. |
8977683000;57223222627; |
The new era of endoscopic ultrasound in biliary disorders |
2021 |
Clinical Journal of Gastroenterology |
14 |
4 |
|
923 |
931 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105339459&doi=10.1007%2fs12328-021-01419-1&partnerID=40&md5=e46386a86669ce1318bf2c07a7eeb843 |
Division of Hepatobiliary, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, JL. Diponegoro 71, Jakarta, DKI Jakarta 10430, Indonesia; Digestive Disease & GI Oncology Centre, Medistra Hospital, Jakarta, Indonesia |
Lesmana, C.R.A., Division of Hepatobiliary, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, JL. Diponegoro 71, Jakarta, DKI Jakarta 10430, Indonesia, Digestive Disease & GI Oncology Centre, Medistra Hospital, Jakarta, Indonesia; Mandasari, B.K.D., Division of Hepatobiliary, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, JL. Diponegoro 71, Jakarta, DKI Jakarta 10430, Indonesia |
Biliary obstruction is one of challenging biliary disorders in gastroenterology field, where this long-standing condition can also lead to portal hypertension and multi-disciplinary teamwork is usually needed to manage this problem. Biliary drainage is the primary management to prevent prolonged cholestasis. Biliary system with its thin-walled and tubular structure sometimes makes the diagnosis and therapeutic not easy to approach. Over the past 3 decades, numerous new and modern diagnostic and therapeutic modalities have been developed to manage the complex biliary problems. It is well known that endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic biliary drainage (PTBD), and surgical procedure are common procedures in managing biliary disorders. However, surgical therapy and ERCP are not always easy to perform due to several contraindications. Because of difficulty in performing these procedures or unavailability of these procedures in the facility, PTBD, as the primary non-surgical procedure of choice, has been popular due to its easy technique. Endoscopic ultrasound (EUS) has evolved significantly not only as a diagnostic tool for identification and staging, but also for interventional approaches, especially in management of biliary malignancy. Recently, EUS-guided biliary drainage (EUS-BD) and EUS-guided gallbladder drainage (EUS-GBD) are developed for managing biliary disorders. Whether EUS can be useful for managing biliary obstruction as a primary procedure is still controversial. Hence, a large number of further studies are required to validate. © 2021, Japanese Society of Gastroenterology. |
Biliary obstruction; Endoscopic ultrasound (EUS); EUS-guided biliary drainage (EUS-BD); EUS-guided gallbladder drainage (EUS-GBD); Portal hypertension |
biliary tract disease; biliary tract drainage; cholestasis; endoscopic retrograde cholangiopancreatography; endoscopic ultrasonography; examination; gallbladder drainage; history of medicine; human; interventional ultrasonography; nonhuman; percutaneous transhepatic drainage; portal hypertension; Review; screening; biliary tract tumor; cholestasis; diagnostic imaging; endoscopic ultrasonography; Biliary Tract Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Drainage; Endosonography; Humans |
Springer Japan |
18657257 |
|
33895970 |
Review |
Q3 |
414 |
11779 |
|
|
|
269 |
Hoenigl M., Salmanton-García J., Walsh T.J., Nucci M., Neoh C.F., Jenks J.D., Lackner M., Sprute R., Al-Hatmi A.M.S., Bassetti M., Carlesse F., Freiberger T., Koehler P., Lehrnbecher T., Kumar A., Prattes J., Richardson M., Revankar S., Slavin M.A., Stemler J., Spiess B., Taj-Aldeen S.J., Warris A., Woo P.C.Y., Young J.-A.H., Albus K., Arenz D., Arsic-Arsenijevic V., Bouchara J.-P., Chinniah T.R., Chowdhary A., de Hoog G.S., Dimopoulos G., Duarte R.F., Hamal P., Meis J.F., Mfinanga S., Queiroz-Telles F., Patterson T.F., Rahav G., Rogers T.R., Rotstein C., Wahyuningsih R., Seidel D., Cornely O.A. |
23090526000;57016722000;57216999195;7006052823;35269375100;56288564200;36676416300;56381466800;56061758400;57196350860;23024401300;55885407200;55877882300;7003278668;57203775508;55841155700;55520616300;34571895200;7006287667;57212303550;7102753307;6602237737;6603670355;7201801340;7004186640;57226896540;57210309976;6507940363;35427566600;55805374500;7003577085;57226519851;55851942844;7005370707;6602209179;55941779900;6603198848;6701765109;7202308156;35482389900;7202088193;7004535145;6507268400;57191968048;7004206966; |
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology |
2021 |
The Lancet. Infectious diseases |
21 |
8 |
|
e246 |
e257 |
|
29 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101404847&doi=10.1016%2fS1473-3099%2820%2930784-2&partnerID=40&md5=c4d3207ffee3c5129eaa933baa93db58 |
Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA; Clinical and Translational Fungal Research Working Group, University of California San Diego, San Diego, CA, USA; European Confederation of Medical Mycology Council, Basel, Switzerland; Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Department of Medicine, Department of Pediatrics, and Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA; New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA; Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Faculty of Pharmacy, Collaborative Drug Discovery Research Group, Pharmaceutical and Life Sciences, Community of Research, Universiti Teknologi MARASelangor, Malaysia; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA; Clinical and Translational Fungal Research Working Group, University of California San Diego, San Diego, CA, USA; Division of General Internal Medicine, Department of Medicine, University of California San Diego, San Diego, CA, USA; Institute of Hygiene and Medical Microbiology, Department of Hygiene, Medical Microbiology and Publics Health, Medical University Innsbruck, Innsbruck, Austria; Faculty of Medicine, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; Department of Microbiology, Natural & Medical Sciences Research Center, University of Nizwa, Nizwa, Oman; Division of Infections Diseases, Department of Health Sciences, IRCCS San Martino Polyclinic Hospital, University of Genoa, Genoa, Italy; Department of Pediatrics, Pediatric Oncology Institute IOP-GRAACC-UNIFESP, Federal Univeristy of São Paulo, São Paulo, Brazil; Centre for Cardiovascular Surgery and Transplantation, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany; Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Frankfurt, Germany; Department of Microbiology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamKochi, India; Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; Mycology Reference Centre Manchester, Manchester University NHS Foundation Trust, Manchester, UK; Division of Infectious Diseases, Wayne State University, MI, Detroit, United States; University of Melbourne, Melbourne, VIC, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Department of Hematology and Oncology, Heidelberg University, Mannheim, University Hospital Mannheim, Germany; Department of Laboratory Medicne and Pathology, Hamad Medical Corporation, Doha, Qatar; Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom; Department of Microbiology, University of Hong Kong, Hong Kong, China; University of Minnesota, MN, Minneapolis, United States; Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany; National Reference Laboratory for Medical Mycology, Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; European Confederation of Medical Mycology Council, Basel, Switzerland; Host-Pathogen Interaction Study Group, Laboratory of Parasitology and Mycology, Angers University Hospital, Angers University, Angers, France; Department of Microbiology, University of Colombo, Colombo, Sri Lanka; Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of DelhiDelhi, India; Center of Expertise in Mycology, Radboud University Medical Center-Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Critical Care Department, Attikon University Hospital, National and Kapodistrian University of Athens, Greece; University Hospital Puerta de Hierro MajadahondaMadrid, Spain; Department of Microbiology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University Olomouc, Olomouc, Czech Republic; European Confederation of Medical Mycology Council, Basel, Switzerland; Department of Medical Microbiology and Infectious Diseases, Radboud University Medical Center-Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Center of Expertise in Mycology, Radboud University Medical Center-Canisius Wilhelmina Hospital, Nijmegen, Netherlands; European Confederation of Medical Mycology Council, Basel, Switzerland; National Institute for Medical Research, Tanzania; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania; Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK; Department of Public Health, Clinics Hospital, Federal University of Parana, Curitiba, Brazil; TX, UT Health San Antonio and South Texas Veterans Health Care System, San Antonio, United States; Sheba Medical Center, Sackler School of Medicine, Tel Aviv UniversityTel Aviv, Israel; Department of Clinical Microbiology, Trinity College Dublin, St James's Hospital Campus, Dublin, Ireland; Division of Infectious Diseases, University of Toronto, ON, Toronto, Canada; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia; Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Clinical Trials Center Cologne, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; European Confederation of Medical Mycology Council, Basel, Switzerland |
Hoenigl, M., Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA; Clinical and Translational Fungal Research Working Group, University of California San Diego, San Diego, CA, USA; European Confederation of Medical Mycology Council, Basel, Switzerland; Salmanton-García, J., Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Walsh, T.J., Department of Medicine, Department of Pediatrics, and Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA; New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA; Nucci, M., Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Neoh, C.F., Faculty of Pharmacy, Collaborative Drug Discovery Research Group, Pharmaceutical and Life Sciences, Community of Research, Universiti Teknologi MARASelangor, Malaysia; Jenks, J.D., Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA; Clinical and Translational Fungal Research Working Group, University of California San Diego, San Diego, CA, USA; Division of General Internal Medicine, Department of Medicine, University of California San Diego, San Diego, CA, USA; Lackner, M., Institute of Hygiene and Medical Microbiology, Department of Hygiene, Medical Microbiology and Publics Health, Medical University Innsbruck, Innsbruck, Austria; Sprute, R., Faculty of Medicine, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; Al-Hatmi, A.M.S., Department of Microbiology, Natural & Medical Sciences Research Center, University of Nizwa, Nizwa, Oman; Bassetti, M., Division of Infections Diseases, Department of Health Sciences, IRCCS San Martino Polyclinic Hospital, University of Genoa, Genoa, Italy; Carlesse, F., Department of Pediatrics, Pediatric Oncology Institute IOP-GRAACC-UNIFESP, Federal Univeristy of São Paulo, São Paulo, Brazil; Freiberger, T., Centre for Cardiovascular Surgery and Transplantation, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Koehler, P., Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany; Lehrnbecher, T., Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Frankfurt, Germany; Kumar, A., Department of Microbiology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa VidyapeethamKochi, India; Prattes, J., Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Graz, Austria; Richardson, M., Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; Mycology Reference Centre Manchester, Manchester University NHS Foundation Trust, Manchester, UK; Revankar, S., Division of Infectious Diseases, Wayne State University, MI, Detroit, United States; Slavin, M.A., University of Melbourne, Melbourne, VIC, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Stemler, J., Faculty of Medicine, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; Spiess, B., Department of Hematology and Oncology, Heidelberg University, Mannheim, University Hospital Mannheim, Germany; Taj-Aldeen, S.J., Department of Laboratory Medicne and Pathology, Hamad Medical Corporation, Doha, Qatar; Warris, A., Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom; Woo, P.C.Y., Department of Microbiology, University of Hong Kong, Hong Kong, China; Young, J.-A.H., University of Minnesota, MN, Minneapolis, United States; Albus, K., Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Arenz, D., Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany; Arsic-Arsenijevic, V., National Reference Laboratory for Medical Mycology, Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; European Confederation of Medical Mycology Council, Basel, Switzerland; Bouchara, J.-P., Host-Pathogen Interaction Study Group, Laboratory of Parasitology and Mycology, Angers University Hospital, Angers University, Angers, France; Chinniah, T.R., Department of Microbiology, University of Colombo, Colombo, Sri Lanka; Chowdhary, A., Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of DelhiDelhi, India; de Hoog, G.S., Center of Expertise in Mycology, Radboud University Medical Center-Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Dimopoulos, G., Critical Care Department, Attikon University Hospital, National and Kapodistrian University of Athens, Greece; Duarte, R.F., University Hospital Puerta de Hierro MajadahondaMadrid, Spain; Hamal, P., Department of Microbiology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University Olomouc, Olomouc, Czech Republic; European Confederation of Medical Mycology Council, Basel, Switzerland; Meis, J.F., Department of Medical Microbiology and Infectious Diseases, Radboud University Medical Center-Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Center of Expertise in Mycology, Radboud University Medical Center-Canisius Wilhelmina Hospital, Nijmegen, Netherlands; European Confederation of Medical Mycology Council, Basel, Switzerland; Mfinanga, S., National Institute for Medical Research, Tanzania; Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania; Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania; Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK; Queiroz-Telles, F., Department of Public Health, Clinics Hospital, Federal University of Parana, Curitiba, Brazil; Patterson, T.F., TX, UT Health San Antonio and South Texas Veterans Health Care System, San Antonio, United States; Rahav, G., Sheba Medical Center, Sackler School of Medicine, Tel Aviv UniversityTel Aviv, Israel; Rogers, T.R., Department of Clinical Microbiology, Trinity College Dublin, St James's Hospital Campus, Dublin, Ireland; Rotstein, C., Division of Infectious Diseases, University of Toronto, ON, Toronto, Canada; Wahyuningsih, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Parasitology, Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia; Seidel, D., Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; Cornely, O.A., Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Clinical Trials Center Cologne, University of Cologne, Cologne, Germany; German Centre for Infection Research, partner site Bonn-Cologne, Cologne, Germany; European Confederation of Medical Mycology Council, Basel, Switzerland |
With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness in preventing many invasive fungal infections, selective pressure has caused an increase of breakthrough infections caused by Fusarium, Lomentospora, and Scedosporium species, as well as by dematiaceous moulds, Rasamsonia, Schizophyllum, Scopulariopsis, Paecilomyces, Penicillium, Talaromyces and Purpureocillium species. Guidance on the complex multidisciplinary management of infections caused by these pathogens has the potential to improve prognosis. Management routes depend on the availability of diagnostic and therapeutic options. The present recommendations are part of the One World-One Guideline initiative to incorporate regional differences in the epidemiology and management of rare mould infections. Experts from 24 countries contributed their knowledge and analysed published evidence on the diagnosis and treatment of rare mould infections. This consensus document intends to provide practical guidance in clinical decision making by engaging physicians and scientists involved in various aspects of clinical management. Moreover, we identify areas of uncertainty and constraints in optimising this management. Copyright © 2021 Elsevier Ltd. All rights reserved. |
|
mycosis; animal; diagnosis; disease management; drug effect; drug therapy; fungus; genetics; human; isolation and purification; medical society; microbiology; mycology; physiology; practice guideline; Animals; Disease Management; Fungi; Humans; Mycology; Mycoses; Practice Guidelines as Topic; Societies, Medical |
NLM (Medline) |
14744457 |
|
33606997 |
Review |
#N/A |
#N/A |
#N/A |
|
|
|
282 |
Lazarus G., Wangsaputra V.K., Christianto, Louisa M., Soetikno V., Hamers R.L. |
57214599425;57215576000;57223348000;41461551400;36769252100;23034345900; |
Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials |
2021 |
Frontiers in Pharmacology |
12 |
|
664875 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111311631&doi=10.3389%2ffphar.2021.664875&partnerID=40&md5=708eaf175b9ad89a98ff6679c222f1c7 |
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom |
Lazarus, G., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Wangsaputra, V.K., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Christianto, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Soetikno, V., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Hamers, R.L., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom |
Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), notably cabotegravir (CAB-LA) and rilpivirine (RPV-LA), for the prevention of human immunodeficiency virus-1 (HIV-1) infection. Methods: Eligible randomized trials of LAI PrEP in HIV-uninfected and/or healthy patients were included and assessed with the Revised Cochrane risk-of-bias tool for randomized trials. Where feasible, a meta-analysis was performed for safety outcomes by using a random-effects model with risk ratios and their 95% confidence intervals as the common effect measure. The protocol was registered with PROSPERO CRD42020154772. Results: Eight studies cumulating a total of 666 participants were included in this systematic review, including five (362 intervention-arm volunteers) and four trials (194 intervention-arm volunteers) that investigated CAB-LA and RPV-LA, respectively. We found that both CAB-LA and RPV-LA were generally well-tolerated as their safety profiles were similar to placebo in terms of any adverse event (AE), serious AE, and AE-related withdrawals. Furthermore, pharmacokinetic analyses revealed favorable prospects in viral inhibitory activity of CAB-LA and RPV-LA. Intramuscular (IM) injection of CAB-LA 600 mg Q8W was superior to CAB-LA 800 mg Q12W in male participants, while the same was true for RPV-LA 1200 mg IM Q8W over other dosing regimens. Although these results are promising, further research is required to confirm the findings on RPV-LA as current evidence is limited. Conclusion: CAB-LA and RPV-LA have promising safety and pharmacokinetic profiles. The preventive efficacy of these agents is being evaluated in Phase 3 trials. © Copyright © 2021 Lazarus, Wangsaputra, Christianto, Louisa, Soetikno and Hamers. |
cabotegravir; HIV-human immunodeficiency virus; long acting injectable (LAI); pre-exposure (PrEP) prophylaxis; rilpivirine |
|
Frontiers Media S.A. |
16639812 |
|
|
Review |
Q1 |
1384 |
2619 |
|
|
|
296 |
Pudjiadi A.H., Pramesti D.L., Pardede S.O., Djer M.M., Rohsiswatmo R., Kaswandani N. |
18435202300;57286438600;57210394278;12771087900;55533574600;57195941745; |
Validation of the vasoactive-inotropic score in predicting pediatric septic shock mortality: A retrospective cohort study |
2021 |
International Journal of Critical Illness and Injury Science |
11 |
3 |
|
117 |
122 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116401748&doi=10.4103%2fIJCIIS.IJCIIS_98_20&partnerID=40&md5=c4a8675dca5d2e706bb5225b224574e6 |
Department of Child-Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia |
Pudjiadi, A.H., Department of Child-Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; Pramesti, D.L., Department of Child-Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; Pardede, S.O., Department of Child-Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; Djer, M.M., Department of Child-Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; Rohsiswatmo, R., Department of Child-Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia; Kaswandani, N., Department of Child-Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Universitas Indonesia, Jakarta, Indonesia |
Introduction: Mortality in pediatric septic shock remains very high. Vasoactive-inotropic score (VIS) is widely used to predict prognosis in patients with heart disease. It is a simple method that was initially used as a predictor of morbidity and mortality in postoperative patients with congenital heart diseases. Previous reports showed that high VIS score was associated with high mortality in pediatric sepsis. However, its discriminative value remains unclear. We aim to explore the discriminative value of VIS in predicting mortality in pediatric septic shock patients. Methods: We conducted a retrospective cohort study on medical records of septic shock patients who received care in the pediatric intensive care unit (PICU). We screened medical records of pediatric patients which were diagnosed with septic shock and admitted to the PICU and received vasoactive/inotropic score for more than 8 h. Other supporting examination results were recorded, such as organ function evaluation for calculation of Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score. The outcome of patients was recorded. The receiver operating curve was constructed to calculate the area under the curve (AUC), sensitivity, and specificity of each cutoff point. Results: We obtained the optimum cutoff point of VIS > 11 with 78.87% sensitivity and 72.22% specificity. AUC positive was 0.779 (P < 0.001); predictive value and negative predictive value were 91.80% and 46.43%, respectively. Conclusion: VIS > 11 has a good ability to predict mortality in children with septic shock. © 2021 International Journal of Critical Illness and Injury Science | Published by Wolters Kluwer-Medknow. |
Mortality; pediatrics; sepsis; vasoactive-inotropic score |
|
Wolters Kluwer Medknow Publications |
22295151 |
|
|
Review |
Q3 |
274 |
15730 |
|
|
|
298 |
Sutandi N., Lee F. |
57201654034;57262177400; |
Vitreoretinal abnormalities in corona virus disease 2019 patients: What we know so far |
2021 |
Taiwan Journal of Ophthalmology |
11 |
3 |
|
232 |
243 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115110995&doi=10.4103%2ftjo.tjo_30_21&partnerID=40&md5=36ea488504463bec350d4e4cb30186ed |
Department of Ophthalmology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia |
Sutandi, N., Department of Ophthalmology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia; Lee, F., Department of Ophthalmology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia |
The coronavirus disease 2019 (COVID-19) has become a global pandemic since December 2019. Although COVID-19 primarily affects the respiratory systems, it has become abundantly clear that it involves multiple organs including the heart, kidney, skin, and brain. Neuro-ophthalmic signs and anterior segment inflammation of the eyes were documented in COVID-19 patients recently. Small but growing number of literatures has also reported the cases of new onset vitreoretinal disorders related to COVID-19 infection. A comprehensive search from four online databases was done. Findings show vitreoretinal involvement in COVID-19 patients including the central retinal vein occlusion, central retinal artery occlusion, reactivation of previous uveitis, chorioretinitis, macular hemorrhage, acute macular neuroretinopathy, paracentral acute middle maculopathy, vitritis with outer retinal abnormalities, varicella zoster virus-related acute retinal necrosis in immunocompromised patient, and other posterior segment pathological changes. The hypotheses for potential pathogenesis of these manifestations are direct viral ocular infection and thromboembolic complications secondary to the hyperinflammatory response. This is the first review article, which provides an overview of current evidence regarding the vitreoretinal manifestations in COVID-19 patients. © 2021 Wolters Kluwer Medknow Publications. All rights reserved. |
COVID-19; funduscopy; posterior segment; SARS-CoV-2; vitreoretinal abnormalities |
|
Wolters Kluwer Medknow Publications |
22115056 |
|
|
Review |
Q3 |
519 |
9760 |
|
|
|
304 |
Gunawan S., Aulia A., Soetikno V. |
57226331078;57201441066;36769252100; |
Development of rat metabolic syndrome models: A review |
2021 |
Veterinary World |
14 |
7 |
|
1774 |
1783 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111179239&doi=10.14202%2fvetworld.2021.1774-1783&partnerID=40&md5=609e64dbfe9d6c9660d991f611abbd71 |
Department of Pharmacology, Faculty of Medicine, Universitas Tarumanagara, Jakarta, Indonesia; Doctoral Programme in Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Gunawan, S., Department of Pharmacology, Faculty of Medicine, Universitas Tarumanagara, Jakarta, Indonesia, Doctoral Programme in Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Aulia, A., Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Soetikno, V., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Metabolic syndrome (MetS) has become a global problem. With the increasing prevalence of MetS worldwide, understanding its pathogenesis and treatment modalities are essential. Animal models should allow an appropriate representation of the clinical manifestations of human conditions. Rats are the most commonly used experimental animals for the study. The development of a proper MetS model using rats will contribute to the successful application of research findings to the clinical setting. Various intervention methods are used to induce MetS through diet induction with various compositions, chemicals, or a combination of both. This review will provide a comprehensive overview of several studies on the development of rat MetS models, along with the characteristics of the clinical manifestations resulting from each study. © 2021 Veterinary World. All rights reserved. |
High-fat diet; High-fructose diet; High-sucrose diet; Metabolic syndrome; Rat models |
cholesterol; diacylglycerol; glucose; high density lipoprotein cholesterol; leptin receptor; low density lipoprotein cholesterol; triacylglycerol; abdominal circumference; abdominal obesity; animal model; bipolar disorder; body weight; bone metabolism; caloric intake; carbohydrate intake; cardiovascular disease; diastolic blood pressure; dyslipidemia; exercise; fat mass; food intake; gene; glucose blood level; glucose tolerance; high-fructose diet; human; hyperglycemia; insulin resistance; insulin sensitivity; insulin tolerance test; lipid diet; lipid metabolism; lipid storage; lipogenesis; major depression; male; mental disease; metabolic syndrome X; nonalcoholic fatty liver; nonhuman; osmotic stress; oxidative stress; pathogenesis; physical activity; prevalence; rat; Review; risk factor; |
Veterinary World |
09728988 |
|
|
Review |
Q2 |
550 |
9187 |
|
|
|
321 |
Kalaij A.G.I., Sugiyanto M., Ilham A.F. |
57223906853;57223907058;57223916865; |
Factors Associated With Vaccination Compliance in Southeast Asian Children: A Systematic Review |
2021 |
Asia-Pacific Journal of Public Health |
33 |
5 |
|
479 |
488 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106426931&doi=10.1177%2f10105395211014640&partnerID=40&md5=5913c1adcdd2be2c2d07170aba4e2029 |
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Kalaij, A.G.I., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sugiyanto, M., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Ilham, A.F., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Although vaccination coverage has reached a peak of 86% globally, around 19.9 million infants and children are yet to receive routine vaccinations—with Asia holding the highest prevalence of noncompliance. This implies notable gaps in vaccination coverage among some regions in the world. This study aims to analyze the factors associated with compliance toward childhood vaccination in Southeast Asia. A systematic review of observational studies was conducted using the following databases: PubMed, Scopus, and Cochrane. Included studies analyze factors affecting compliance with childhood vaccination in Southeast Asia, and assessed with Joanna Briggs Institute (JBI) and Newcastle-Ottawa Scale’s criteria. Sixteen observational studies were included, with a total of 41 956 subjects, consisting of 15 cross-sectional studies and one case-control study. Our results suggested that parental personal–related, children and family status–related, socioeconomic, and health care–related factors strongly affected subjects’ compliance with immunization. Prominent determinants were older maternal age, higher economics groups, parents in government or health care sectors, and frequent antenatal care visits. On the other hand, noncompliance were associated with younger age, large quantity of family members, lower economic groups, lower education, and unemployed parents. We hope that this comprehensive assessment thoroughly addresses challenges and inform strategies to raise compliance toward childhood vaccination in Southeast Asia. © 2021 APJPH. |
childhood vaccination; compliance; factors; Southeast Asia |
case control study; child; childhood; controlled study; cross-sectional study; education; educational status; female; government; health care cost; human; human experiment; infant; male; maternal age; Medline; Newcastle-Ottawa scale; observational study; prenatal care; review; Scopus; Southeast Asia; Southeast Asian; systematic review; unemployment; vaccination; article |
SAGE Publications Inc. |
10105395 |
|
34013786 |
Review |
Q2 |
572 |
8837 |
|
|
|
325 |
Gondhowiardjo S.A., Handoko, Tham I., Giselvania A., Bilimagga R.S., Octavianus S., Hiraoka M., Jayalie V.F., Tamaki T., Calaguas M., Nakano T. |
6508327402;57209984822;56736361800;57217201891;16038470700;57217198334;57202560109;57195939736;18538545200;8452403700;35353843800; |
Regional collaboration to improve quality of radiation therapy in Asia |
2021 |
Journal of Medical Imaging and Radiation Oncology |
65 |
4 |
|
424 |
430 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097537491&doi=10.1111%2f1754-9485.13133&partnerID=40&md5=d4d03b15e65e131d0dbd6e9674b257d4 |
Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Radiation Oncology Centre, Mt Elizabeth Novena Hospital, Singapore City, Singapore; Department of Radiation Oncology, HealthCare Global (HCG) Enterprises (Bangalore Institute of Oncology), Bangalore, Karnataka, India; Department of Radiation Oncology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan; Department of Radiation Oncology, Fukushima Medical University, Fukushima, Japan; Division of Radiation Oncology, Department of Radiology, University of the Philippines, Philippine General Hospital, Manila, Philippines; Quantum Medical Science Directorate, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan |
Gondhowiardjo, S.A., Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Handoko, Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Tham, I., Radiation Oncology Centre, Mt Elizabeth Novena Hospital, Singapore City, Singapore; Giselvania, A., Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Bilimagga, R.S., Department of Radiation Oncology, HealthCare Global (HCG) Enterprises (Bangalore Institute of Oncology), Bangalore, Karnataka, India; Octavianus, S., Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Hiraoka, M., Department of Radiation Oncology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan; Jayalie, V.F., Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Tamaki, T., Department of Radiation Oncology, Fukushima Medical University, Fukushima, Japan; Calaguas, M., Division of Radiation Oncology, Department of Radiology, University of the Philippines, Philippine General Hospital, Manila, Philippines; Nakano, T., Quantum Medical Science Directorate, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan |
In Asia, several challenges hinder the delivery of high-quality cancer treatment, especially radiation therapy (RT). Many Asian countries face large-scale shortage of RT centres and treatment machines. Additionally, there is also a significant technological gap, with many RT centres in Asia still using outdated technology. There is an urgent need to improve radiation treatment quality in Asia. The Federation of Asian Organizations for Radiation Oncology (FARO) was set up to foster regional collaboration, which we believe can help to identify and solve some of these issues collectively. This report describes the background and rationale of starting FARO, and puts forth some of the early achievements of the group, including fact-finding and educational activities. Finally, we discuss future possibilities, including strategic proposals that may benefit the RT community and our patients in Asia. © 2020 The Royal Australian and New Zealand College of Radiologists |
Asia; cancer; quality; radiation therapy; regional collaboration |
achievement; adult; article; Asia; cancer radiotherapy; human; organization; radiation oncology; radiotherapy; Asia; radiation oncology; Asia; Humans; Radiation Oncology |
Blackwell Publishing |
17549477 |
|
33319494 |
Review |
Q3 |
310 |
14491 |
|
|
|
328 |
Sihotang R.C., Alvonico T., Taher A., Birowo P., Rasyid N., Atmoko W. |
57216755881;57216743520;7005269743;6504153311;56245069300;57193125664; |
Premature ejaculation in patients with lower urinary tract symptoms: a systematic review |
2021 |
International Journal of Impotence Research |
33 |
5 |
|
516 |
524 |
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084492871&doi=10.1038%2fs41443-020-0298-5&partnerID=40&md5=243ef2c5fa8e96c70ec2e3eb9ca5b534 |
Faculty of Medicine, Universitas Indonesia, No. 6, Salemba Raya Road, DKI Jakarta, 10430, Indonesia; Department of Urology, Cipto Mangunkusumo National Hospital, Diponegoro Road, DKI Jakarta, 10430, Indonesia |
Sihotang, R.C., Faculty of Medicine, Universitas Indonesia, No. 6, Salemba Raya Road, DKI Jakarta, 10430, Indonesia; Alvonico, T., Faculty of Medicine, Universitas Indonesia, No. 6, Salemba Raya Road, DKI Jakarta, 10430, Indonesia; Taher, A., Department of Urology, Cipto Mangunkusumo National Hospital, Diponegoro Road, DKI Jakarta, 10430, Indonesia; Birowo, P., Department of Urology, Cipto Mangunkusumo National Hospital, Diponegoro Road, DKI Jakarta, 10430, Indonesia; Rasyid, N., Department of Urology, Cipto Mangunkusumo National Hospital, Diponegoro Road, DKI Jakarta, 10430, Indonesia; Atmoko, W., Department of Urology, Cipto Mangunkusumo National Hospital, Diponegoro Road, DKI Jakarta, 10430, Indonesia |
Lower urinary tract symptoms (LUTS) refer to a group of symptoms related to bladder, prostate, and urethra. LUTS are common in men and the severity increases with age. LUTS are frequently associated with sexual dysfunction, such as premature ejaculation (PE), standing as the most common sexual dysfunction in men. Both LUTS and PE cause distress and dissatisfaction for the patient and his partner. This systematic review aims to determine the relationship between LUTS and PE in men. Two reviewers independently conduct a literature search in five online databases (PubMed, Scopus, Proquest, ClinicalKey, and ScienceDirect). In addition, reviewers also reviewed the reference list of chosen articles to identify additional relevant studies. Twelve articles were included in this systematic review that consists of one cohort study and 11 cross-sectional studies. The total scores of each identified study ranged from “poor” to “good.” The prevalence of PE in LUTS ranged from 12 to 77%. Most of the studies showed a significant relationship between LUTS and PE. PE is more common in older age with the peak prevalence in age of 60–69 years old. There is a possible association between PE and LUTS. Further research using cohort or case-control study design on this topic is needed. © 2020, The Author(s), under exclusive licence to Springer Nature Limited. |
|
age; human; International Prostate Symptom Score; male; outcome assessment; premature ejaculation; prevalence; prostatectomy; Review; systematic review; urinary tract infection; aged; case control study; cohort analysis; complication; cross-sectional study; ejaculation; lower urinary tract symptom; middle aged; premature ejaculation; Aged; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Ejaculation; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Premature Ejaculation |
Springer Nature |
09559930 |
|
32393845 |
Review |
Q2 |
508 |
9947 |
|
|
|
333 |
Ngadimin K.D., Stokes A., Gentile P., Ferreira A.M. |
57224568038;57224586577;24478479500;16068361700; |
Biomimetic hydrogels designed for cartilage tissue engineering |
2021 |
Biomaterials Science |
9 |
12 |
|
4246 |
4259 |
|
15 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107619348&doi=10.1039%2fd0bm01852j&partnerID=40&md5=634f8d458d06a53948b28ba7237188d1 |
Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; Faculty of Medicine, Universitas Indonesia, Indonesia; Faculty of Science, Agriculture and Engineering, Newcastle University, Newcastle upon Tyne, United Kingdom |
Ngadimin, K.D., Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, Faculty of Medicine, Universitas Indonesia, Indonesia; Stokes, A., Faculty of Science, Agriculture and Engineering, Newcastle University, Newcastle upon Tyne, United Kingdom; Gentile, P., Faculty of Science, Agriculture and Engineering, Newcastle University, Newcastle upon Tyne, United Kingdom; Ferreira, A.M., Faculty of Science, Agriculture and Engineering, Newcastle University, Newcastle upon Tyne, United Kingdom |
Cartilage regeneration and repair remain a clinical challenge due to the limited capability of cartilage to self-regenerate. Worldwide, the costs associated with cartilage regeneration per patient are estimated on average £30 000 for producing and supplying cells. Regenerative approaches may include the use of cell therapies and tissue engineering by combining relevant cells, scaffolds and instructive biomolecules to stimulate or modulate cartilage repair. Hydrogels have been of great interest within these fields to be used as 3D substrates to cultivate and grow cartilage cells. Currently, biomimetic hydrogels with adequate biological and physicochemical properties, such as mechanical properties, capable of supporting load-bearing capability, are yet to succeed. In this review, biomaterials' advantages and disadvantages for the manufacturing of biomimetic hydrogels for cartilage regeneration are presented. Different studies on the formulation of cartilage-like hydrogels based on materials such as gelatin, chondroitin sulfate, hyaluronic acid and polyethylene glycol are summarised and contrasted in terms of their mechanical properties (e.g. elastic modulus) and ability to enhance cell function such as cell viability and GAG content. Current limitations and challenges of biomimetic hydrogels for cartilage regeneration are also presented. © 2021 The Royal Society of Chemistry. |
|
Biomechanics; Biomimetics; Cartilage; Cells; Cytology; Hyaluronic acid; Hydrogels; Mechanical properties; Molecular biology; Physicochemical properties; Scaffolds (biology); Sulfur compounds; Tissue; Biomimetic hydrogels; Cartilage cells; Cartilage regeneration; Cartilage repair; Cartilage tissue engineering; Chondroitin sulfates; Current limitation; Load bearing capabilities; Cell engineering; biomaterial; biomimetic material; chondroitin sulfate; gelatin; hyaluronic acid; hydrogel; macrogol; biological activity; biomimetics; cartilage; cell therapy; cell viability; chemical composition; computer model; cross linking; human; in vitro study; nonhuman; Review; tissue engineering; tissue regeneration; Young modulus; articular cartilage; biomimetics; cartilage; hydrogel; regeneration; tissue |
Royal Society of Chemistry |
20474830 |
|
33710205 |
Review |
Q1 |
1422 |
2479 |
|
|
